“…The activity of CAT, which is an essential antioxidant, was found to be significantly diminished in PCa patients. There are conflicting results in the literature regarding the role of the CAT (C-262T) gene polymorphism in PCa (Choi et al, 2007;Battisti et al, 2011;Karunasinghe et al, 2012;Tefik et al, 2013;Geybels et al, 2015;Hu et al, 2015). Geybels et al (2015) suggested that CAT gene polymorphism is associated with stage III/IV prostate cancers.…”